Commentary|Podcasts|August 25, 2023
ESG Evolution
Author(s)Nicholas Saraceno, Editor
In this PC Podcast episode, Susanne Katus discusses the increasing number of regulations impacting both pharma and biotech companies.
Advertisement
In this exclusive PC Podcast interview, Susanne Katus, SVP, market leader, corporate secretary at Datamaran, a platform that monitors and analyzes risk factors, dives into:
- The growing number of environmental, social, and governance (ESG) regulations impacting these aforementioned businesses
- Where the responsibility lies for them in terms of ESG compliance
- What can be done in order for these corporations to be ahead of the game
- Why ESG should be a top priority
The latest episode of The Pharmaceutical Commerce Podcast is available directly on SoundCloud.
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
The Great Repricing: How Pharma Must Evolve for Three Diverging Payer Economies
2
The Longer-Term Impact of MFN Pricing
3
The ROI Moment Pharma Keeps Missing: Point-of-Care as Revenue Protection
4
Trade & Channel Strategies 2025: The $405 Billion Patent Cliff Demands Partnership and Adaptive Market Access Strategies
5
